City

Seoul (1)

Condition

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (2)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 2 (2)

Sponsor

Akeso (1)

Asan Medical Center (1)

Collaborator

Intervention

5-fluorouracil (1)

ak117 (1)

cadonilimab (1)

docetaxel (1)

docetaxel, oxaliplatin, s-1 and durvalumab (1)

durvalumab and tremelimumab (1)

oxaliplatin (1)

tegafur-gimeracil-oteracil potassium (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

resectable gastric or gastroesophageal junction adenocarcinoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)

Not yet recruiting

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Cadonilimab
+5 more

(no location specified)

Jul 17, 2023

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Seoul (Docetaxel, Oxaliplatin, S-1 and Durvalumab,

Recruiting

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Docetaxel, Oxaliplatin, S-1 and Durvalumab
Durvalumab and Tremelimumab

Seoul, Korea, Republic of

Asan Medical Center

Jun 1, 2020